EUCTR2006-003066-34-DE进行中（未招募）不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.
ETI Pharma GmbH0 个研究点开始时间: 2006年11月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients of both gender aged from 18 up to 65 years
- •2.Prior to study specific examinations the patient has to give his/her written informed consent
- •3.At least 2 exacerbations of eczema or permanent skin lesions during the last 2 months
- •4.Patients have to suffer from atopic eczema (with or without rhinitis and/or rhinoconjunctivitis) impaired by clinical sensitization against House dust mites (HDM) leading to an aggravation of skin lesions. The sensitization against House dust mites (HDM) has to be verified by*
- •·Symptom aggravation of skin lesions by exposure to House dust mites (HDM) and during winter season
- •·A positive skin prick test for Dermatophagoides pteronyssinus (Der p) and/or Dermatophagoides farinae (Der f), resulting in a wheal diameter of at least 4 mm > negative control reaction or '++' versus histamine
- •·Specific IgE for Der p or Der f CAP-RAST > 3
- •5.The diagnosis atopic eczema has to be verified according to the criteria of Hanifin and Rajka
- •6.Duration of atopic eczema > 5 years
- •7.Encasings of bedding and mattress for more than 6 months (or stable environmental control)
- •*Additionally an atopy patch test with Der p and Der f will be performed in selected study sites but not be used as inclusion criterion
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The following therapy is not allowed within the last 5 years prior to screening as well as during the study and will prevent the patient from being included into the study:
- •·Specific Immunotheraphy with House dust mites (HDM)
- •2.The following therapy is not allowed within within 3 months prior to screening as well as during the study and will prevent the patient from being included into the study:
- •·Photopheresis
- •3.The following medications and therapies are not allowed within the last month prior to screening as well as during the study and will prevent the patient from being included into the study:
- •·Immunosuppressive agents (cyclosporins, mycophenolates)
- •·Systemic corticosteroids
- •·UV-therapy, tanning
- •4.The following medications and therapies are not allowed during the entire study and will lead to the patient being withdrawn:
- •·b-blocker
- •·Treatment with substances interfering with the immune system
- •5.Total SCORAD < 30, documented by digital photography
- •6.Patients with therapeutically uncontrolled atopic eczema or erythrodermia
- •7.Patients with 3 consecutive exacerbations within 12-24 hours after immunotherapy
- •Patients with other known concomitant diseases / treatments
- •8.Active tuberculosis
- •9.Acute and chronic inflammatory or infectious diseases at the target organ
- •10.Advanced secondary changes at the target organ (e.g. emphysema or bronchiectasis)
- •11.Immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role
- •12.Immune deficiencies
- •13.Uncontrolled asthma, defined as FEV1 or PEF = 70% of predicted normal value
- •14.Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism)
- •15.Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
- •16.Malignant disease of any kind during the previous 5 years
- •17.Abnormal laboratory parameters and vital signs that could increase the risk to the study participant
- •18.Alcohol, drug or medication abuse within the past year
- •19.Severe psychiatric or neurologic disorders
- •20.Patients who are expected to be non-compliant and/or not co-operative
- •21.Participation in any other clinical study within the last 30 days prior to the start of the study
- •22.Patients who have already participated in this study
- •23.Patients who are employees at the investigational site, relatives or spouses of the investigator
- •24.Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- •25.Patients who are not contractually capable
- •Special restrictions for female patients
- •26.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation
- •27.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or hysterectomy or are u
研究者
相似试验
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleEUCTR2006-003067-31-LTETI Pharma GmbH230
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleRhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.MedDRA version: 8.1Level: LLTClassification code 10039083Term: RhinitisEUCTR2006-003067-31-DEETI Pharma GmbH230
进行中（未招募）
不适用
A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen - N/AEUCTR2004-001538-18-SEETI Pharma GmbH70
进行中（未招募）
1 期
A trial to test the effect of BL-8040 or placebo given to AML patients in addition to standard treatment in masked manner.consolidation therapy in acute myeloid leukemia in first complete remissionMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-002702-21-DEMartin-Luther-Universität Halle- Wittenberg194
已完成
2 期
Effects of perioperative Recombinant Human Erythropoietin administration on proinflammatory cascade following breast cancer surgery.Female subjects with breast cancer stage II/III undergoing a modified radical mastectomyCancer - BreastInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12610000813088niversity Hospital of Ioannina22